4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000008
Chief Executive Officer sold 18,703 shares at $27.09 ($506,664)
- Chief Executive Officer acquired 38,278 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Goff Brian · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-12-30 | Exercise or conversion : show line 1 in the form 10b5-1 | +25,528 | 149,056 | D | ||
| 2025-12-30 | Sale : show line 2 in the form 10b5-1 | −12,473 | $27.09 | $337,894 | 136,583 | D |
| 2025-12-30 | Exercise or conversion : show line 3 in the form 10b5-1 | +12,750 | 149,333 | D | ||
| 2025-12-30 | Sale : show line 4 in the form 10b5-1 | −6,230 | $27.09 | $168,771 | 143,103 | D |
| Open-market sales · 18,703 sh · avg $27.09 · $506,664 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-12-30 | Exercise or conversion : show line 5 in the form 10b5-1 Performance share units | −25,528 | 25,528 | D |
| 2025-12-30 | Exercise or conversion : show line 6 in the form 10b5-1 Performance share units | −12,750 | 0 | D |
Loading xslF345X05/wk-form4_1767402967.xml…